Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Inclusion Criteria: * Histologically or cytologically confirmed stage IIIB/IV lung cancer with EGFR mutation * Progressed after platinum-based chemotherapy * The last anti-tumor therapy before entering this study must be gefitinib, erlotinib or icotinib, and the duration for tumor response must be no less than 4 months, or the duration for stable disease must be no less than 6 months * With a measurable disease with conventional CT) according to RECIST Criteria * WHO performance status(PS)\<= 2 * N\>=1.5×109/L, Plt\>=1.0×109/L,Hb\>=9g/dL; AST\&ALT should \<2.5ULN(without liver metastasis) or \<5ULN(with liver metastasis).TBIL\<=1.5ULN. * Signed and dated informed consent before the start of specific protocol procedures. Exclusion Criteria: * Allergic to icotinib or arsenic trioxide. * Patients with metastatic brain tumors with symptoms. * Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases.